MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Andrographolide

CAS No. : 5508-58-7

MCE 站：Andrographolide

产品活性：Andrographolide 是一种 NF-κB 抑制剂，通过共价修饰内皮细胞中 p50 的半胱氨酸残基而抑制 NF-κB 活化，而不影响 IκBα 降解或 p50/p65 核易位。Andrographolide 具有抗病毒作用。

研究领域：NF-κB  |  Anti-infection  |  Autophagy

作用靶点：NF-κB  |  SARS-CoV  |  Influenza Virus  |  Autophagy

In Vitro: Andrographolide (AP) concentration-dependently suppresses receptor activator of nuclear factor kappa B ligand (RANKL)-mediated osteoclast differentiation and bone resorption in vitro and reduces the expression of osteoclast-specific markers. Andrographolide attenuates inflammation by inhibition of TNFα-induced NF-κB activation through covalent modification of reduced Cys⁶² of p50, without affecting IκBα degradation or p50/p65 nuclear translocation. Andrographolide also inhibits the ERK/MAPK signalling pathway without affecting p38 or JNK signalling. Andrographolide inhibits osteoclast differentiation of RAW 264.7 cells in a concentration-dependent manner. Andrographolide suppresses osteoclast formation in a concentration-dependent manner without any obvious cytotoxic effects, in both BMMs and RAW 264.7 cells. Andrographolide treatment substantially reduces the area of bone resorption. Only approximately 30% of the bone resorption observed in the control group is achieved after treatment with 2.5?μM Andrographolide. Osteoclastic bone resorption is almost completely inhibited after treatment with 10?μM Andrographolide.

In Vivo: Treatment with Andrographolide (5 or 30?mg/kg) reduces the extent of bone loss induced by LPS. Moreover, Andrographolide slightly increases the BMD and cortex thickness compared to LPS treatment. Histological examination confirms the protective effects of Andrographolide on LPS-induced bone loss. LPS injection leads to inflammatory bone erosion and increased numbers of TRAP-positive osteoclasts.

相关产品：Covalent Screening Library Plus  |  Natural Product Library Plus  |  Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Immunology/Inflammation Compound Library  |  NF-κB Signaling Compound Library  |  Stem Cell Signaling Compound Library  |  Natural Product Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Antiviral Compound Library  |  Autophagy Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Covalent Screening Library  |  Antioxidants Compound Library  |  Differentiation Inducing Compound Library  |  Oxygen Sensing Compound Library  |  Anti-COVID-19 Compound Library  |  NMPA-Approved Drug Library  |  Medicine Food Homology Compound Library  |  Terpenoids Library  |  Pyroptosis Compound Library  |  Traditional Chinese Medicine Monomer Library  |  FDA Approved & Pharmacopeial Drug Library  |  Anti-Breast Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Chloroquine  |  Acetylcysteine  |  Dexamethasone  |  Bortezomib  |  U0126-EtOH  |  Tunicamycin  |  Hydroxychloroquine sulfate  |  Pyrrolidinedithiocarbamate ammonium  |  Vadimezan  |  Favipiravir  |  Curcumin  |  Imatinib  |  Aloxistatin  |  Camptothecin  |  Thapsigargin  |  Aprotinin  |  JSH-23  |  Imiquimod  |  Camostat mesylate  |  Shikonin  |  Oseltamivir acid  |  Ivermectin  |  Geldanamycin  |  Auranofin  |  Triptolide  |  Emricasan  |  Rocaglamide  |  Dihydroartemisinin  |  GRL0617

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。